Vitamin D3 supplementation has no effect on conventional cardiovascular risk factors: a parallel-group, double-blind, placebo-controlled RCT

J Clin Endocrinol Metab. 2012 Oct;97(10):3557-68. doi: 10.1210/jc.2012-2126. Epub 2012 Aug 3.

Abstract

Context: Observational studies show an association between low vitamin D status assessed by circulating 25-hydroxyvitamin D and cardiovascular events and mortality. Data from randomized controlled trials are limited.

Objective: The aim of this study was to test whether daily doses of vitamin D(3) at 400 or 1000 IU/d for 1 yr affected conventional markers of cardiovascular disease (CVD) risk.

Design: We conducted a parallel-group, double-blind, placebo-controlled randomized controlled trial. Randomization was computer generated. Participants and study investigators were blinded to intervention groupings throughout the trial.

Setting: The study was conducted at the Clinical Research Facility, University of Aberdeen, United Kingdom.

Participants: A total of 305 healthy postmenopausal women aged 60-70 yr were recruited for the study.

Intervention: Each woman received a daily capsule of 400 or 1000 IU vitamin D(3) or placebo randomly allocated.

Main outcome measures: Primary outcomes were serum lipid profile [total, high-density lipoprotein, and low-density lipoprotein cholesterol; triglycerides; and apolipoproteins A-1 and B100], insulin resistance (homeostatic model assessment), inflammatory biomarkers (high-sensitivity C-reactive protein, IL-6, soluble intracellular adhesion molecule-1), and blood pressure.

Results: A total of 265 (87%) participants completed all study visits. Small differences between groups for serum apolipoprotein B100 change [repeated measures ANOVA, P=0.04; mean (sd), -1.0 (10.0) mg/dl (400 IU); -1.0 (10.0) mg/dl (1000 IU); and +0.02 (10.0) mg/dl (placebo)] were not considered clinically significant. Other systemic markers for CVD risk remained unchanged. There was significant seasonal variation in systolic and diastolic blood pressure independent of vitamin D dose (P<0.001, linear mixed model). Mean (sd) reduction in systolic blood pressure from winter to summer was -6.6 (10.8) mm Hg.

Conclusions: Improving vitamin D status through dietary supplementation is unlikely to reduce CVD risk factors. Confounding of seasonality should be recognized and addressed in future studies of vitamin D.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biomarkers / metabolism
  • Cardiovascular Diseases / mortality*
  • Cholecalciferol / administration & dosage*
  • Cholecalciferol / adverse effects
  • Double-Blind Method
  • Female
  • Humans
  • Middle Aged
  • Placebos
  • Postmenopause*
  • Risk Factors
  • Risk Reduction Behavior
  • Vitamins / administration & dosage*
  • Vitamins / adverse effects

Substances

  • Biomarkers
  • Placebos
  • Vitamins
  • Cholecalciferol

Associated data

  • ISRCTN/ISRCTN20328039